Ketamine Infusions vs Nerve Blocks for Neuropathic Pain: A Clinical Comparison

A fast comparison: head-to-head snapshot and quick verdict

What does it look like when “standard neuropathy meds” have already failed? Picture a common consult: refractory diabetic neuropathy, burning feet, sleep wrecked, mood sliding, and they’ve already done the rounds, gabapentin, duloxetine, maybe a TCA, plus topical lidocaine. They’re not asking for miracles. They want a plan that doesn’t just reshuffle meds and side effects.

Here’s the quick verdict. Ketamine Infusions vs Nerve Blocks isn’t really a “which is stronger” debate; it’s a “where is the pain being generated and maintained” question. Ketamine often wins when the pattern looks centralized, wind-up, allodynia, widespread neuropathic pain, with anxiety or depression riding shotgun. Nerve blocks and pulsed radiofrequency tend to shine when there’s a localized peripheral generator (entrapment, post-surgical focal neuropathy), or when you need diagnostic clarity plus temporary relief. In our Quakertown, PA clinic (Dr. Bruce Richman, ASKP³-Certified Ketamine Care), we also factor in mental health, safety considerations, transportation to and from the clinic, and how this choice interacts with tapering plans for opioids, Suboxone, kratom, or benzodiazepines.

Many patients exploring Ketamine Therapy for Neuropathic Pain start by reading Ketamine for chronic pain a non opioid option because the “non-opioid” angle matters when dependency and withdrawal symptoms are already part of the story.

A caveat upfront: Ketamine vs Nerve Blocks isn’t an either-or decision forever. Some of the most durable plans combine them, sequenced around function goals, not just pain scores.

How ketamine infusions work vs how nerve blocks and pulsed radiofrequency act

Fact: ketamine works “upstream” of the pain signal. The headline is NMDA receptor antagonism, which matters because NMDA activity is a major driver of central sensitization, the stuck-on amplification where normal input feels like fire. Clinically, what matters is what can follow NMDA modulation: glutamate signaling quiets down, pain circuits can de-escalate, and the brain gets a chance to relearn safer patterns. Stanford’s pain group describes ketamine as doing more than blocking pain; it may help reprogram pain pathways through neuroplasticity (Stanford’s overview of ketamine for chronic pain).

In practice, most chronic neuropathic protocols use low-dose, subanesthetic IV infusions, not psychedelic-level dosing. That distinction matters for safety and for setting expectations. UCSF’s pain education site describes inpatient ketamine as a continuous infusion in the microgram/kg/min range, and notes outpatient use for mixed neuropathic pain conditions (UCSF Pain Management Education on ketamine dosing and use). Translation: physician-led protocols, careful monitoring, and dose titration based on response and side effects, not a one-size-fits-all drip.

Downstream biology gets discussed a lot, and some of it's still evolving, but here’s the clinically useful frame. Ketamine can influence synaptogenesis and BDNF-related signaling (the “new connections” conversation), and it may dampen microglial activation, one reason it’s been explored in conditions with neuroinflammation components. That overlap helps explain why some patients notice improvements in pain and mood, especially when depression and pain are feeding each other.

By contrast, nerve blocks are a focal, mechanical, targeted strategy. The mechanism is straightforward: local anesthetics (sometimes with steroid, depending on the target and rationale) reduce sodium channel, mediated conduction, so the nerve can’t transmit pain signals effectively. Clinically, blocks are often diagnostic first. If numbing nerve X drops pain by ~70% for a few hours, you’ve learned something valuable about the generator. Therapeutic blocks can buy time for rehab, sleep, and reduced reliance on rescue meds, especially meaningful when you’re also tapering and trying to avoid spiraling into dependency.

Pulsed radiofrequency is a different tool than “burning a nerve.” The pulsed radiofrequency mechanism is neuromodulation, not neurodestruction. By delivering short bursts of RF energy at controlled temperatures, it appears to alter axonal signaling and dorsal root ganglion activity without creating the same lesion you’d see with continuous RF. That’s why it’s often considered when you want longer relief than a block, but you’re trying to preserve function and avoid numbness.

So the real contrast is systemic versus focal. Ketamine-based care makes more sense when pain is distributed, when there’s allodynia, sleep disruption, and a clear central sensitization pattern. Blocks and pulsed RF tend to make more sense when there’s a clean map to follow: one nerve, one dermatome, one surgical scar line, one entrapment point.

Clinical implication, the way we explain it in the room:

• If pain feels like a “volume knob stuck on high” across a region (and mood is tangled in it), ketamine is often the better first swing.
• If pain is reliably traceable to a nerve (and a block can prove it), blocks or pulsed RF usually give a cleaner, more efficient win.

And if you’re worried about stigma or confusion around this treatment, it’s worth reading Debunking ketamine therapy myths facts and insights because the biggest decision errors we see come from misunderstanding dosing, monitoring, and what “rapid relief” actually means in chronic neuropathic pain.

Key Takeaways

• Ketamine-based care fits centralized, widespread symptoms and mood comorbidity, while blocks or pulsed RF suit focal entrapment patterns.
• Use a diagnostic nerve block when a single nerve distribution is suspected, then plan pulsed RF if relief is clear.
• Expect ketamine onset within hours to days with relief lasting weeks to months, often needing repeat courses.
• Expect nerve blocks to relieve pain immediately but briefly, while pulsed RF can extend benefit for months.
• Screen for psychiatric history and uncontrolled hypertension before ketamine, and for infection or bleeding risk before procedures.
• Plan logistics and costs upfront since ketamine often needs monitored infusions and may be out-of-pocket, unlike covered blocks.

Expected outcomes and duration of relief: what patients typically experience

Some treatments are slow burns. Ketamine infusions aren’t usually one of them. Many patients feel a shift in pain within hours to a few days, sometimes even during the infusion series itself. UCSF’s pain education materials describe inpatient dosing as a continuous infusion and note outpatient use for mixed neuropathic pain conditions, which fits what we see clinically: the early effect can be real, but durability is the big variable (UCSF’s ketamine overview for pain clinicians).

Duration is harder to predict than onset. Some people get a couple of good weeks, others get a few months, and some only feel a brief window. The VA’s 2024 update on ketamine infusion for intractable neuropathic pain highlights a practical pattern: longer (multihour) infusion courses over several days can translate into longer relief, but it’s not a guarantee. That’s why most physician-led protocols are built around an initial series, then maintenance based on response, function, and safety considerations.

Nerve blocks behave differently. A diagnostic block can provide immediate relief, sometimes within minutes, and that “lightswitch effect” is clinically useful because it tells you whether you’ve found the right pain generator. Duration ranges widely: a few hours (local anesthetic only) to days or weeks (when steroid is added). If the block is repeatedly helpful but short-lived, pulsed radiofrequency (pRF) is often the next step, with many patients reporting relief that lasts months, especially when the target is well-localized.

Responder rates depend heavily on the condition. CRPS often responds to NMDA-antagonist strategies more than, say, long-standing diabetic neuropathy, where central sensitization is only part of the story. Post-herpetic neuralgia and post-surgical neuropathy can go either way, some patients do better with a targeted interventional approach, others need a central “reset” plus rehab. A clinically meaningful win is typically a 2-point drop on a 0, 10 pain scale or roughly a 30% reduction, but the better yardstick is function: walking farther, sleeping through the night, using fewer rescue meds.

One thing patients don’t always expect is the mental health piece. Ketamine therapy can improve mood, sleep, and pain catastrophizing in some people because of neuroplasticity effects, not just short-term analgesia. We’ve had patients say, “My pain isn’t gone, but it stopped running my life,” which is often the first step toward tapering other meds safely.

When you’re planning follow-up, think in timelines. For outcomes, we usually reassess within 1, 2 weeks after the initial infusion series, then decide on maintenance or a different strategy. For blocks, reassess within days, because the diagnostic value fades if you wait too long. And if you’re juggling dependency, withdrawal symptoms, or complex medication changes, our team keeps coordination tight, especially in cases involving Suboxone or kratom, like in this discussion of Ketamine and suboxone interaction in kratom tapering, where personalized care and monitoring matter.

Evidence base: trials, meta-analyses, and gaps for both approaches

The evidence story is clearest on one point: IV ketamine can reduce neuropathic pain in the short term, while long-term certainty is harder to claim. Systematic reviews and health technology assessments generally conclude it can reduce pain in chronic non-cancer and neuropathic conditions, but the trials are small, protocols vary, and follow-up is often measured in days to weeks, not months. Canada’s 2023 health technology review is a good example: it found meaningful short-term relief alongside higher rates of adverse effects, which is exactly the trade-off clinicians manage in real life (Canada’s 2023 update on IV ketamine for chronic non-cancer pain).

For specific neuropathic subtypes, the most consistent signal is in CRPS, where central sensitization and NMDA-mediated wind-up are prominent. In PHN and diabetic neuropathy, results are more mixed, partly because peripheral nerve injury, microvascular changes, and central amplification contribute in different proportions across patients. Stanford’s pain program has also emphasized that ketamine’s impact isn’t only “blocking pain”. It may help re-pattern maladaptive pain circuits, which is a plausible mechanism for why some patients get longer benefit than the drug’s half-life would suggest (Stanford’s discussion of ketamine and pain-pathway “reprogramming”).

Nerve blocks have a different kind of evidence base. For many conditions, their best-supported role is diagnostic and prognostic: if blocking a nerve or plexus reliably drops pain and improves function, you’ve learned something actionable. Therapeutic blocks can help during flares or to enable PT, but durability is inconsistent, and repeated steroid exposure isn’t trivial. Where the data gets more interesting is pulsed radiofrequency trials, which aim to modulate pain signaling without creating a destructive lesion. PRF has RCTs and cohort data in select indications (for example, certain cranial neuralgias and focal neuropathic syndromes), and when the target is correct, months of relief is realistic. The limitation is that outcomes are very target- and technique-dependent, and not every neuropathic pain syndrome has a single “culprit nerve” you can reliably treat.

Guidelines and expert consensus reflect that split. Ketamine is often positioned as an option for refractory neuropathic pain, especially when standard neuropathic agents fail or aren’t tolerated, but there’s no universal dosing standard. A 2023 CME review from the Neuropathic Pain Special Interest Group notes there’s still no consensus on optimal infusion rates, which is why physician-led protocols vary and why careful titration and monitoring are part of basic safety considerations (NRAP Pain CME on ketamine infusion rates for neuropathic pain). On the interventional side, blocks and pRF are typically recommended when symptoms map to an anatomic distribution and when imaging, exam, and response to diagnostic injection line up.

The biggest gap is obvious: we don’t have enough head-to-head trials comparing ketamine infusions versus pRF (or other interventional pathways) in the same, well-phenotyped neuropathic populations with long follow-up. Future studies need standardized dosing schedules, clearer responder definitions (pain plus function), and cost-effectiveness analyses that include downstream medication changes like tapering opioids or gabapentinoids. Long-term safety also needs more attention, both for ketamine exposure over time and for cumulative interventional procedures.

In practice, the evidence supports a trial when pain is widespread, centrally amplified, or intertwined with sleep and mental health symptoms. Blocks and pRF make more sense when the pai

n generator is local and testable. In Quakertown, PA, Dr. Bruce Richman’s ASKP³-Certified Ketamine Care model leans into that reality: personalized care, tight monitoring, and coordination for complex cases like chronic pain with anxiety/depression, cerebral palsy-related pain, or patients navigating Suboxone, kratom, or benzodiazepine dependence, where rapid relief is valuable, but only if it’s paired with a plan that prevents new dependency problems.

Safety profile and side effects: systemic risks vs procedural complications

A fair way to think about safety is this: ketamine trades a “whole-body” risk profile for a potentially broader upside. The most common acute side effects around an IV infusion are dissociation (feeling detached or “floaty”), nausea, dizziness, and short-lived increases in blood pressure and heart rate. Most of that peaks during the infusion and fades over 30 to 90 minutes, but it can leave you foggy for the rest of the day.

Neuropsychiatric effects matter, especially if you've a history of panic, psychosis, or poorly controlled PTSD. Ketamine can temporarily intensify anxiety or perceptual changes, which is why physician-led protocols and a calm, monitored setting aren’t optional. If you want a deeper, plain-English explanation of what’s happening centrally, the article on Ketamine effects on brain and body neurobiological insights ties the clinical experience to neuroplasticity and why some patients report rapid relief.

Longer-term concerns are real, but they’re usually about dose and frequency. High-dose, chronic exposure has been linked with bladder toxicity (urgency, frequency, pelvic pain) and can also stress the liver in some patients, so many programs check baseline labs and repeat them if a course is extended. The VA’s clinical update on ketamine infusion protocols for intractable neuropathic pain (va.gov) also emphasizes monitoring and infusion duration as key safety considerations.

Nerve blocks and pulsed radiofrequency (RF) flip the equation. The medication stays local, so systemic effects are usually minimal, but complications are procedural: bleeding, infection, temporary numbness or weakness (an unintended motor block), and rare nerve injury. There’s also local anesthetic systemic toxicity (LAST), which is uncommon but serious, and it’s why reputable procedure suites keep lipid rescue and resuscitation equipment immediately available.

Pulsed RF is generally considered less destructive than conventional (thermal) RF, since it’s designed to modulate rather than “burn” tissue. That said, technique and targeting matter, and the risk doesn’t drop to zero.

Here’s the practical comparison most patients actually care about:

Mitigation is straightforward when the clinic is set up for it. For ketamine, that means pre-infusion screening, conservative titration, and recovery-area observation, plus a plan for tapering other sedatives or opioids when appropriate so you don’t get blindsided by withdrawal symptoms. For blocks and RF, ultrasound or fluoroscopic guidance, timeouts, and a team that does these procedures routinely reduce avoidable misses and complications.

One honest caveat: neither option is “set it and forget it.” If your pain is driven by severe mechanical compression (for example, a nerve trapped by a mass), you’ll often need structural treatment first, and these become bridges, not cures.

At Dr. Bruce Richman’s ASKP³-Certified clinic in Quakertown, PA, our team builds personalized care plans that weigh pain control, mental health stability, and safety considerations together, including support for chronic pain, depression, anxiety, ADD, and complex dependency cases (Suboxone, kratom, opiates, benzodiazepines), with transportation to and from the clinic when patients shouldn’t drive after treatment.

Cost, logistics, and access: what patients and clinics should plan for

Sticker price is often where the two paths diverge fastest. Ketamine infusions are commonly quoted per visit, and many patients need a short “loading” series, often 3 to 6 infusions over 1 to 2 weeks, before spacing treatments out. In many regions, a single outpatient infusion lands roughly in the mid-hundreds to low-thousands range, and multi-day protocols (longer sessions or consecutive days) can climb from there depending on monitoring intensity and facility fees.

Nerve blocks are usually priced per procedure, and the number can vary based on whether it’s a simple diagnostic injection, a series, or pulsed RF afterward. Blocks can look less expensive upfront, but repeat procedures add up, especially if relief is short-lived or if the plan requires staged diagnostics before RF.

Coverage is the other big separator. Insurance-covered nerve blocks are often covered when documentation supports a clear pain generator and conservative care has failed. Prior authorization is common but not unusual. Infusions for neuropathic pain are still frequently out-of-pocket, even when the medical rationale is strong, because payer policies lag behind clinical use and coding can be inconsistent.

Logistics are different too. Ketamine requires a monitored infusion space, trained staff, and recovery time. Patients should plan on not driving the same day, and many appreciate having transportation arranged because cognitive effects can linger even after you feel “back to normal.” Blocks and RF require a procedure room, sterile supplies, imaging guidance, and post-procedure observation, but the visit is often shorter and the after-effects are more localized.

Access depends on where you live. Urban areas tend to have more infusion programs and interventional pain practices. Rural patients may travel for either. Pulsed RF also hinges on credentialing and operator experience, so availability can be patchy.

In Quakertown, PA, our physician-led protocols are built around real-world constraints: scheduling that fits work and caregiving, transportation to and from the clinic when needed, and coordinated planning when pain overlaps with mental health, tapering goals, or a history of dependency.

Who is the best candidate for each therapy? A decision algorithm clinicians can use

What actually determines whether a patient improves, medication choice, procedure type, or selection? In practice, selection wins. Match the intervention to the pain phenotype and both ketamine infusions and nerve blocks can be high-yield. Miss the match, and you’ll burn time, money, and trust.

Patient phenotyping: when ketamine vs when blocks win

Central sensitization has a recognizable “fingerprint.” Features that lean toward Ketamine Therapy for Neuropathic Pain include widespread burning, allodynia that’s out of proportion to local findings, disrupted sleep, and a pain narrative that has clearly outgrown the original injury. These patients often carry depression/anxiety or significant psychological strain, and they’ve already failed a reasonable multi-modal peripheral plan (PT, topical agents, membrane stabilizers, injections). Stanford’s pain program frames ketamine as more than analgesia, it may interrupt maladaptive signaling and support neuroplasticity in entrenched pain circuits (Stanford overview of ketamine for chronic pain).

By contrast, nerve blocks (and pulsed RF when appropriate) tend to win when the problem is local and reproducible. Think focal neuropathic pain in a single nerve distribution, clear entrapment or post-surgical nerve irritation, and a trigger you can reliably provoke on exam. When a diagnostic block produces meaningful short-term relief, that’s not “just symptom control.” It’s a map, evidence that you’ve identified a treatable generator and a defensible target for longer-acting strategies.

Contraindications and caution flags that change the plan

One fact worth stating plainly: ketamine isn’t “no big deal.” Caution flags include uncontrolled hypertension, unstable cardiac disease, significant urinary dysfunction (especially baseline frequency/urgency), and psychiatric history where dissociation could destabilize symptoms. If there’s concern about dependency, tapering, or withdrawal from other substances, that doesn’t automatically exclude ketamine. It does push you toward tighter screening, clearer boundaries, and physician-led protocols with explicit safety considerations.

Procedural therapies have a different risk profile. For blocks and pulsed RF, the red flags are practical and immediate: infection at the site, systemic infection, coagulopathy/anticoagulation that can’t be safely managed, or simply no defensible target on exam and imaging. “No target” is a real contraindication, because a vague injection teaches the patient nothing, and it often erodes confidence in the next (more appropriate) step.

A practical 5-step decision algorithm

1. Phenotype the pain: focal vs widespread, peripheral generator vs centralized features, and baseline function (NRS plus PROMIS/ODI if you use them).
2. Risk screen: BP, psych history, urinary symptoms for ketamine. Bleeding/infection risk for procedures.
3. Test what needs testing: EMG/NCS when the distribution is unclear, ultrasound/MRI when entrapment is suspected.
4. If focal, do a diagnostic block first: document percent relief and duration. A “positive” block (often 50%+ relief) supports nerve block workflow escalation and potential pulsed RF.
5. If centralized or multi-territory, initiate ketamine: consider sequencing (infusion first to calm the system, then targeted blocks) or combining when both peripheral and central drivers are present.

A documentation tip that saves headaches later: write down the patient’s goal in one line (sleep, walking tolerance, return to work) and the tradeoffs they accept (transient dissociation vs procedure discomfort). That single sentence becomes the spine of informed consent.

If you’re deciding who benefits from ketamine, the most useful shorthand is this: when the nervous system itself has become the pain generator, an infusion is often the more logical first move. And if you’re building a program, the dosing conversation matters, which is why we lean on resources like Safer Ketamine Therapy with Precise Dosing to keep plans disciplined, measurable, and reproducible.

A real-world treatment pathway and how to implement it in clinic (with consent and follow-up steps)

Picture this: a patient walks in who has done “everything right,” and they’re still suffering.

A 52-year-old with 3 years of post-surgical neuropathic leg pain shows up exhausted. The pain started focal, then spread. They’ve tried gabapentin, PT, topical lidocaine, and two “blind” injections that didn’t help. Mood is sliding, sleep is broken, and they’re worried about medication dependency because they’ve had rough withdrawal symptoms in the past when tapering other meds.

Instead of jumping straight to the most aggressive option, we start with phenotyping and a focused exam. Because there’s still a strong peroneal distribution component, we do a diagnostic block first. It helps, but only for about a day, and only partially. That result matters: it suggests a peripheral generator is present, yet it’s not the whole story.

A clinic-ready pathway

1. Baseline phenotyping + risk screening
   Capture NRS, PROMIS (or ODI), BP, psychiatric history, urinary symptoms, substance history, and a transportation plan. Set expectations up front: ketamine can offer rapid relief in some patients, but it’s not a permanent nerve “fix,” and durability varies.

2. Diagnostic block if focal findings exist
   This is your nerve block workflow gate. Document anesthetic used, target, percent relief, and duration. Provide clear post-procedure restrictions and red-flag instructions (new weakness, fever, progressive swelling, severe headache after neuraxial procedures, or any concerning neurologic change).

3. Trial ketamine infusion course (ketamine infusion protocol)
   Use continuous monitoring and standardized consent that covers dissociation, blood pressure changes, nausea, and post-visit driving restrictions. UCSF describes inpatient infusion ranges commonly in the 1, 5 mcg/kg/min zone, with outpatient use for mixed neuropathic conditions (UCSF ketamine dosing education). For refractory neuropathic pain, the VA notes that longer multihour outpatient infusions across several days can extend benefit (VA 2024 ketamine infusion update). Build in physician-led protocols and explicit safety considerations, especially when mental health comorbidity is part of the picture.

4. Reassess and set maintenance
   Recheck pain and function on a timeline patients can understand: within 1 week for early signal, then again at 2 weeks for trend. If the patient gets meaningful relief, schedule maintenance with a clear interval and criteria to continue (function gains, not just pain scores). If benefits fade quickly, reconsider the driver, the diagnosis, and whether the infusion parameters, or the overall plan, need to change.

5. Escalate thoughtfully
   When the diagnostic block is clearly positive but short-lived, discuss pulsed RF or other neuromodulation referral. When ketamine helps globally but a focal nerve still “breaks through,” combining therapies can be reasonable, one calms the system, the other treats the local generator.

A candid caveat: the evidence base for ketamine in chronic pain is mixed, and not every patient responds, even with careful phenotyping and dosing. That uncertainty is exactly why objective follow-up (function plus pain scores) and predefined stop/continue criteria are essential.

Consent + education checklist

• Expected benefits and what “success” means (sleep, walking, work tolerance)
• Side effects, including transient perceptual changes, BP elevation, and nausea
• Transportation to and from clinic for ketamine days, plus no driving afterward
• Activity limits after blocks, anticoagulant plan if relevant
• Outcome measures used (NRS, PROMIS, ODI) and the follow-up date

If you want a model that’s already operationalized, our team in Quakertown, PA runs ASKP³-Certified care with personalized care plans for chronic pain and neuropathic pain, plus programs that intersect with mental health and complex dependency histories (including Suboxone & Kratom dependence, opiate and benzodiazepine dependence). We also coordinate transportation and medical monitoring for patients where safety and logistics are the limiting factors, not motivation. Clinicians and patients looking for Dr. Bruce Richman clinic ketamine program details can reach out for an individualized assessment and a clean, documented pathway.

Frequently Asked Questions

Can ketamine infusions cure neuropathic pain?

No, ketamine infusions don’t reliably cure neuropathic pain. They can deliver meaningful short- to medium-term relief for some people, especially when central sensitization is driving symptoms, but results vary. Many patients need repeat infusion series or booster treatments to maintain gains. Most clinicians also pair infusions with multimodal care like physical therapy, sleep support, and non-opioid medications to improve function and durability.

When should a diagnostic nerve block be used before considering pulsed radiofrequency?

Use a diagnostic nerve block before pulsed radiofrequency when the pain is focal and you suspect a specific nerve or ganglion is the main generator. A short-lived but clear reduction in pain after the block supports that target and makes a therapeutic procedure more defensible. If the block doesn’t help, it’s a sign to reconsider the diagnosis, broaden the workup, or choose a different treatment approach.

Are ketamine infusions safe for patients with depression and neuropathic pain?

They can be safe for patients with depression and neuropathic pain, but only with careful screening and monitoring. Ketamine may improve mood and pain in some patients, yet dissociation, anxiety, blood pressure changes, or other psychotropic effects can occur during treatment. Coordinate with a mental health clinician when possible, confirm stability of psychiatric conditions, and set a clear plan for follow-up.

How do I choose between ketamine and pulsed RF for a patient with CRPS?

Choose based on the CRPS phenotype and where the pain seems to be generated. Infusion-based treatment often fits better when CRPS is diffuse, centrally mediated, or marked by widespread allodynia and sensitization. Pulsed RF or sympathetic-focused interventions may make more sense when there’s a clear regional pattern suggesting a sympathetic generator. Diagnostic blocks and multidisciplinary input can help you pick the most targeted, least invasive next step.

References

1. "Ketamine for Chronic Pain: What to Know Before Starting ." (painnews.stanford.edu) https://painnews.stanford.edu/news/ketamine-chronic-pain-treatment
2. "Ketamine – Pain Management Education at UCSF" (pain.ucsf.edu) https://pain.ucsf.edu/non-opioid-analgesics/ketamine
3. "Ketamine Infusion for the Treatment of Intractable ." (va.gov) https://www.va.gov/formularyadvisor/DOC_PDF/CRE_Ketamine_Infusion_for_the_Treatment_of_Intractable_Neuropathic_Pain_Update_DEC_2024.pdf
4. "Relief from Chronic Neuropathic Pain with Ketamine but . – Springer" (link.springer.com) https://link.springer.com/protocol/10.1007/978-1-0716-4599-4_4
5. "What to Know About Ketamine Therapy for Pain Management" (healthline.com) https://www.healthline.com/health/ketamine-therapy-for-pain-management
6. "Navigating Nerve Blocks: US-Guided Nerve Blocks Vs. Sub-Dissociative ." (rebelem.com) https://rebelem.com/navigating-nerve-blocks-us-guided-nerve-blocks-vs-sub-dissociative-ketamine/
7. "Investigating the effectiveness of oral ketamine on pain ." (frontiersin.org) https://www.frontiersin.org/journals/pain-research/articles/10.3389/fpain.2023.1268985/full
8. "Ketamine for Chronic Non-Cancer Pain: A 2023 Update" (canjhealthtechnol.ca) https://canjhealthtechnol.ca/index.php/cjht/article/view/RC1521/1737
9. "Ketamine: No clear benefit for chronic pain – NeuRA" (neura.edu.au) https://neura.edu.au/news-media/media-releases/no-clear-benefit-ketamine-use-for-chronic-pain-under-scrutiny
10. "Ketamine for Neuropathic Pain: Optimal Infusion Rates- CME" (nrappain.org) https://www.nrappain.org/pages/blog?p=ketamine-for-neuropathic-pain